Latest Australasian Market News

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Intelligent Monitoring Group (ASX:IMB) has finalized its A$37 million purchase of Wormald NZ and Red Wolf, expanding its New Zealand footprint and projecting a 20.9% accretion in earnings per share.

Intelligent Monitoring Group has officially closed its $45 million acquisition of BlueSky Holdco, adding Tyco NZ and Red Wolf Security to its New Zealand portfolio and boosting its local workforce to over 500.

Cuscal has secured the final regulatory approval from the French Works Council, paving the way to complete its $27 million acquisition of New Zealand payments provider Paymark by late May.

Integral Diagnostics has confirmed Jason Martinez will take over as Managing Director and CEO in August 2026, with Dr Ian Kadish remaining in charge until then to ensure a smooth transition.

Shriro Holdings reported solid half-year growth with revenue up 8.4% and NPAT rising 10%, underpinned by strong BBQ and kitchen appliance sales. The company reaffirmed its EBITDA guidance and announced a $15 million off-market share buy-back for FY26.

Spark New Zealand has teamed up with Challenger Limited to offload $240 million in interest free payment receivables, reducing net debt and fueling mobile growth.

Smartpay Holdings Limited’s shares have been suspended from the ASX following New Zealand’s High Court approval of its acquisition by Shift4 Holdings Limited, marking a significant milestone in the payment processing sector.

Smartpay Holdings has secured final court approval for its acquisition by Shift4 Holdings, setting the stage for share suspension and delisting in early November. Shareholders will receive NZ$1.20 per share in cash upon completion, pending final conditions.

Smartpay Holdings has entered a definitive agreement to be acquired by US-based Shift4 Payments for NZ$1.20 per share, representing a significant premium and a near NZ$300 million valuation. The deal, recommended unanimously by Smartpay’s board, awaits shareholder and regulatory approvals.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

ARB Corporation Limited reported a 5.9% increase in sales revenue to $361.7 million for the half year ended December 2024, while profit margins slightly contracted. Strategic acquisitions in the US and Australasia underpin the company’s cautious optimism for future growth.